Fardis Maria
SEC insider (Form 3/4/5 filer). CIK 0001559231. Director at Obsidian Therapeutics, Inc. (OBX) and 1 other issuer. 3 reported Form 4/5 transactions since Sep 2024; latest on Aug 3, 2026. Located in CAMBRIDGE, MA.
Companies Fardis Maria has filed insider reports for
- Obsidian Therapeutics, Inc. (OBX): Director
- CRISPR Therapeutics AG (CRSP): Director
Fardis Maria
CIK: 0001559231
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Aug 3, 2026OBX
Obsidian Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
37.7K shares- - Jun 5, 2026CRSP
CRISPR Therapeutics AG
AwardDirectStock Option (Right to Buy)
13K shares- - Jun 5, 2025CRSP
CRISPR Therapeutics AG
AwardDirectStock Option (Right to Buy)
13K shares-
1-3 of 3 transactions